Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2022-02-16 AGM Information
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and is marked as a '정정신고' (Correction Report). It details the rescheduling of an Extraordinary General Meeting, including the agenda items such as merger approval and director appointments. This falls under the category of Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information and agenda for an upcoming meeting.
2022-02-16 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Aprogen MED) titled 'Change in Sales or Profit/Loss Structure (30% or more)'. This is a standard preliminary earnings announcement required by the Korea Exchange (KRX) when there is a significant change in financial performance compared to the previous year. It provides key financial highlights (revenue, operating profit, net income) but explicitly states that these are preliminary figures subject to change by external auditors. As it is an initial announcement of financial results rather than a full report or a simple publication notice, it falls under the 'Earnings Release' category. FY 2021
2022-02-15 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Aprogen MED) regarding the adjustment of the conversion price for convertible bonds due to a decline in market price. This type of disclosure is a standard capital structure update related to financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate classification for adjustments to conversion prices of debt instruments.
2022-02-14 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in market price. This type of disclosure, which details changes to capital structure instruments like conversion prices, falls under the 'Capital/Financing Update' category as it directly relates to the company's financing activities and capital structure adjustments.
2022-01-28 Korean
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a corporate merger (회사합병 결정) between Aprogen Medicines and Aprogen. It details the merger schedule, merger ratio, valuation methods, and legal requirements for shareholder voting and appraisal rights. This is a formal regulatory filing related to M&A activity, which falls under the 'M&A Activity' category.
2022-01-21 Korean
[기재정정]주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal regulatory filing titled '주주총회소집결의' (Resolution for Convening a General Meeting of Shareholders) and is marked as a '정정신고(보고)' (Correction Report). It details the rescheduling of an Extraordinary General Meeting, including the agenda items such as merger approval and director appointments. This falls under the category of proxy-related information and meeting notices, which is best classified as Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information for an upcoming vote.
2022-01-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.